

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes

**Quincy S. C. Chu · Bahram Forouzesh · Samira Syed ·
Monica Mita · Garry Schwartz · Joshua Cooper ·
Janet Curtright · Eric K. Rowinsky**

Published online: 13 April 2007
© Springer Science + Business Media, LLC 2007

The publisher apologizes for the error in this article that appears on the website. Joshua Copper's name is incorrectly spelled and should appear as Joshua Cooper.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-006-9031-6>.

Q. S. C. Chu (✉)
Cross Cancer Institute,
11560 University Avenue,
Edmonton, AB T6G 1Z2, Canada
e-mail: quincchu@cancerboard.ab.ca

B. Forouzesh · S. Syed · M. Mita · J. Cooper · J. Curtright ·
E. K. Rowinsky
Institute for Drug Development, Cancer Therapy and Research Center,
University of Texas Health Sciences Center,
San Antonio, TX, USA

G. Schwartz
Brooke Army Medical Center,
Fort Sam Houston, TX, USA